nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Anorexia—Ifosfamide—testicular cancer	0.00239	0.00239	CcSEcCtD
Dicyclomine—Malaise—Cisplatin—testicular cancer	0.00239	0.00239	CcSEcCtD
Dicyclomine—Decreased appetite—Dactinomycin—testicular cancer	0.00238	0.00238	CcSEcCtD
Dicyclomine—Fatigue—Dactinomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Dicyclomine—Pain—Dactinomycin—testicular cancer	0.00234	0.00234	CcSEcCtD
Dicyclomine—Urticaria—Bleomycin—testicular cancer	0.00233	0.00233	CcSEcCtD
Dicyclomine—Lethargy—Epirubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Dicyclomine—Dizziness—Vinblastine—testicular cancer	0.0023	0.0023	CcSEcCtD
Dicyclomine—Mood swings—Methotrexate—testicular cancer	0.00229	0.00229	CcSEcCtD
Dicyclomine—Diplopia—Epirubicin—testicular cancer	0.00226	0.00226	CcSEcCtD
Dicyclomine—Feeling abnormal—Dactinomycin—testicular cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Nausea—Chlorambucil—testicular cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Paraesthesia—Ifosfamide—testicular cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Ill-defined disorder—Etoposide—testicular cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00224	0.00224	CcSEcCtD
Dicyclomine—Dyspnoea—Ifosfamide—testicular cancer	0.00223	0.00223	CcSEcCtD
Dicyclomine—Somnolence—Ifosfamide—testicular cancer	0.00223	0.00223	CcSEcCtD
Dicyclomine—Discomfort—Cisplatin—testicular cancer	0.00223	0.00223	CcSEcCtD
Dicyclomine—Affect lability—Epirubicin—testicular cancer	0.00222	0.00222	CcSEcCtD
Dicyclomine—Vomiting—Vinblastine—testicular cancer	0.00221	0.00221	CcSEcCtD
Dicyclomine—Malaise—Etoposide—testicular cancer	0.00219	0.00219	CcSEcCtD
Dicyclomine—Breast disorder—Methotrexate—testicular cancer	0.00218	0.00218	CcSEcCtD
Dicyclomine—Face oedema—Epirubicin—testicular cancer	0.00218	0.00218	CcSEcCtD
Dicyclomine—Decreased appetite—Ifosfamide—testicular cancer	0.00218	0.00218	CcSEcCtD
Dicyclomine—Headache—Vinblastine—testicular cancer	0.00218	0.00218	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Abdominal pain—Dactinomycin—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Fatigue—Ifosfamide—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Oedema—Cisplatin—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Anaphylactic shock—Cisplatin—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Hypersensitivity—Bleomycin—testicular cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Pain—Ifosfamide—testicular cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Constipation—Ifosfamide—testicular cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Mood swings—Epirubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Loss of consciousness—Etoposide—testicular cancer	0.00213	0.00213	CcSEcCtD
Dicyclomine—Lethargy—Doxorubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Dicyclomine—Nervous system disorder—Cisplatin—testicular cancer	0.00212	0.00212	CcSEcCtD
Dicyclomine—Tachycardia—Cisplatin—testicular cancer	0.00211	0.00211	CcSEcCtD
Dicyclomine—Asthenia—Bleomycin—testicular cancer	0.0021	0.0021	CcSEcCtD
Dicyclomine—Hypertension—Etoposide—testicular cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Diplopia—Doxorubicin—testicular cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Pruritus—Bleomycin—testicular cancer	0.00207	0.00207	CcSEcCtD
Dicyclomine—Feeling abnormal—Ifosfamide—testicular cancer	0.00207	0.00207	CcSEcCtD
Dicyclomine—Nausea—Vinblastine—testicular cancer	0.00206	0.00206	CcSEcCtD
Dicyclomine—Anorexia—Cisplatin—testicular cancer	0.00206	0.00206	CcSEcCtD
Dicyclomine—Affect lability—Doxorubicin—testicular cancer	0.00206	0.00206	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00205	0.00205	CcSEcCtD
Dicyclomine—Discomfort—Etoposide—testicular cancer	0.00204	0.00204	CcSEcCtD
Dicyclomine—Breast disorder—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Dicyclomine—Face oedema—Doxorubicin—testicular cancer	0.00202	0.00202	CcSEcCtD
Dicyclomine—Hypersensitivity—Dactinomycin—testicular cancer	0.00202	0.00202	CcSEcCtD
Dicyclomine—Confusional state—Etoposide—testicular cancer	0.002	0.002	CcSEcCtD
Dicyclomine—Muscular weakness—Epirubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Dicyclomine—Urticaria—Ifosfamide—testicular cancer	0.00199	0.00199	CcSEcCtD
Dicyclomine—Abdominal pain—Ifosfamide—testicular cancer	0.00198	0.00198	CcSEcCtD
Dicyclomine—Anaphylactic shock—Etoposide—testicular cancer	0.00198	0.00198	CcSEcCtD
Dicyclomine—Mood swings—Doxorubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Dicyclomine—Abdominal distension—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Asthenia—Dactinomycin—testicular cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Paraesthesia—Cisplatin—testicular cancer	0.00194	0.00194	CcSEcCtD
Dicyclomine—Tachycardia—Etoposide—testicular cancer	0.00193	0.00193	CcSEcCtD
Dicyclomine—Dyspnoea—Cisplatin—testicular cancer	0.00193	0.00193	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—testicular cancer	0.00192	0.00192	CcSEcCtD
Dicyclomine—Breast disorder—Doxorubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Dicyclomine—Anorexia—Etoposide—testicular cancer	0.00189	0.00189	CcSEcCtD
Dicyclomine—Decreased appetite—Cisplatin—testicular cancer	0.00188	0.00188	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00187	0.00187	CcSEcCtD
Dicyclomine—Vomiting—Bleomycin—testicular cancer	0.00186	0.00186	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—testicular cancer	0.00186	0.00186	CcSEcCtD
Dicyclomine—Rash—Bleomycin—testicular cancer	0.00185	0.00185	CcSEcCtD
Dicyclomine—Pain—Cisplatin—testicular cancer	0.00185	0.00185	CcSEcCtD
Dicyclomine—Dermatitis—Bleomycin—testicular cancer	0.00185	0.00185	CcSEcCtD
Dicyclomine—Hypersensitivity—Ifosfamide—testicular cancer	0.00185	0.00185	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Dicyclomine—Asthenia—Ifosfamide—testicular cancer	0.0018	0.0018	CcSEcCtD
Dicyclomine—Feeling abnormal—Cisplatin—testicular cancer	0.00178	0.00178	CcSEcCtD
Dicyclomine—Paraesthesia—Etoposide—testicular cancer	0.00178	0.00178	CcSEcCtD
Dicyclomine—Pruritus—Ifosfamide—testicular cancer	0.00177	0.00177	CcSEcCtD
Dicyclomine—Dyspnoea—Etoposide—testicular cancer	0.00176	0.00176	CcSEcCtD
Dicyclomine—Somnolence—Etoposide—testicular cancer	0.00176	0.00176	CcSEcCtD
Dicyclomine—Nausea—Bleomycin—testicular cancer	0.00174	0.00174	CcSEcCtD
Dicyclomine—Drowsiness—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Dicyclomine—Vomiting—Dactinomycin—testicular cancer	0.00174	0.00174	CcSEcCtD
Dicyclomine—Rash—Dactinomycin—testicular cancer	0.00172	0.00172	CcSEcCtD
Dicyclomine—Decreased appetite—Etoposide—testicular cancer	0.00172	0.00172	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00171	0.00171	CcSEcCtD
Dicyclomine—Fatigue—Etoposide—testicular cancer	0.00171	0.00171	CcSEcCtD
Dicyclomine—Constipation—Etoposide—testicular cancer	0.00169	0.00169	CcSEcCtD
Dicyclomine—Pain—Etoposide—testicular cancer	0.00169	0.00169	CcSEcCtD
Dicyclomine—Dizziness—Ifosfamide—testicular cancer	0.00166	0.00166	CcSEcCtD
Dicyclomine—Feeling abnormal—Etoposide—testicular cancer	0.00163	0.00163	CcSEcCtD
Dicyclomine—Nausea—Dactinomycin—testicular cancer	0.00162	0.00162	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Etoposide—testicular cancer	0.00162	0.00162	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Dicyclomine—Vomiting—Ifosfamide—testicular cancer	0.00159	0.00159	CcSEcCtD
Dicyclomine—Hypersensitivity—Cisplatin—testicular cancer	0.00159	0.00159	CcSEcCtD
Dicyclomine—Rash—Ifosfamide—testicular cancer	0.00158	0.00158	CcSEcCtD
Dicyclomine—Dermatitis—Ifosfamide—testicular cancer	0.00158	0.00158	CcSEcCtD
Dicyclomine—Urticaria—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Dicyclomine—Abdominal pain—Etoposide—testicular cancer	0.00156	0.00156	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Dicyclomine—Asthenia—Cisplatin—testicular cancer	0.00155	0.00155	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—testicular cancer	0.00155	0.00155	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—testicular cancer	0.00151	0.00151	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—testicular cancer	0.0015	0.0015	CcSEcCtD
Dicyclomine—Nausea—Ifosfamide—testicular cancer	0.00149	0.00149	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—testicular cancer	0.00146	0.00146	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Dicyclomine—Hypersensitivity—Etoposide—testicular cancer	0.00146	0.00146	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—testicular cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Dicyclomine—Asthenia—Etoposide—testicular cancer	0.00142	0.00142	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Dicyclomine—Pruritus—Etoposide—testicular cancer	0.0014	0.0014	CcSEcCtD
Dicyclomine—Vomiting—Cisplatin—testicular cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Rash—Cisplatin—testicular cancer	0.00136	0.00136	CcSEcCtD
Dicyclomine—Dermatitis—Cisplatin—testicular cancer	0.00136	0.00136	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—testicular cancer	0.00135	0.00135	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Dicyclomine—Tension—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Dicyclomine—Dizziness—Etoposide—testicular cancer	0.00131	0.00131	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Dicyclomine—Nausea—Cisplatin—testicular cancer	0.00128	0.00128	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Dicyclomine—Vomiting—Etoposide—testicular cancer	0.00126	0.00126	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Dicyclomine—Rash—Etoposide—testicular cancer	0.00125	0.00125	CcSEcCtD
Dicyclomine—Dermatitis—Etoposide—testicular cancer	0.00125	0.00125	CcSEcCtD
Dicyclomine—Headache—Etoposide—testicular cancer	0.00124	0.00124	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Dicyclomine—Nausea—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Dicyclomine—Shock—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—testicular cancer	0.00104	0.00104	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Dicyclomine—Pain—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—testicular cancer	0.001	0.001	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—testicular cancer	0.000996	0.000996	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—testicular cancer	0.000989	0.000989	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—testicular cancer	0.000986	0.000986	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—testicular cancer	0.000979	0.000979	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—testicular cancer	0.000977	0.000977	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—testicular cancer	0.000977	0.000977	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—testicular cancer	0.00097	0.00097	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—testicular cancer	0.000965	0.000965	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000958	0.000958	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—testicular cancer	0.000957	0.000957	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—testicular cancer	0.000949	0.000949	CcSEcCtD
Dicyclomine—Pain—Epirubicin—testicular cancer	0.000949	0.000949	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—testicular cancer	0.000942	0.000942	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—testicular cancer	0.000937	0.000937	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—testicular cancer	0.000929	0.000929	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—testicular cancer	0.000922	0.000922	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—testicular cancer	0.000915	0.000915	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—testicular cancer	0.000914	0.000914	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—testicular cancer	0.000913	0.000913	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000907	0.000907	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—testicular cancer	0.000904	0.000904	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—testicular cancer	0.000892	0.000892	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—testicular cancer	0.000885	0.000885	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—testicular cancer	0.000881	0.000881	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—testicular cancer	0.000878	0.000878	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—testicular cancer	0.000878	0.000878	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—testicular cancer	0.000877	0.000877	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—testicular cancer	0.000874	0.000874	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—testicular cancer	0.000851	0.000851	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—testicular cancer	0.000846	0.000846	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00084	0.00084	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—testicular cancer	0.000839	0.000839	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—testicular cancer	0.000818	0.000818	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—testicular cancer	0.000816	0.000816	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—testicular cancer	0.000812	0.000812	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—testicular cancer	0.000796	0.000796	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—testicular cancer	0.000784	0.000784	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—testicular cancer	0.000756	0.000756	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—testicular cancer	0.000754	0.000754	CcSEcCtD
Dicyclomine—Rash—Methotrexate—testicular cancer	0.000748	0.000748	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—testicular cancer	0.000747	0.000747	CcSEcCtD
Dicyclomine—Headache—Methotrexate—testicular cancer	0.000743	0.000743	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—testicular cancer	0.000737	0.000737	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—testicular cancer	0.000734	0.000734	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—testicular cancer	0.000726	0.000726	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—testicular cancer	0.000704	0.000704	CcSEcCtD
Dicyclomine—Rash—Epirubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—testicular cancer	0.000699	0.000699	CcSEcCtD
Dicyclomine—Headache—Epirubicin—testicular cancer	0.000695	0.000695	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—testicular cancer	0.000679	0.000679	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—testicular cancer	0.000659	0.000659	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—testicular cancer	0.000653	0.000653	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—testicular cancer	0.000647	0.000647	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—testicular cancer	0.000647	0.000647	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—testicular cancer	0.000643	0.000643	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—testicular cancer	0.00061	0.00061	CcSEcCtD
